Literature DB >> 15918184

Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma.

Jun Cui1, Bao-Wei Dong, Ping Liang, Xiao-Ling Yu, De-Jiang Yu.   

Abstract

AIM: The aims of this study were to explore individualized treatment method for hepatocellular carcinoma (HCC) patients whose maximum tumor size was less than 5 cm to improve prognosis and survival quality.
METHODS: Thirty cases of primary HCC patients undergoing tumor resection were retrospectively analyzed (resection group). All the tumors were proved as primary HCC with pathologic examination. The patients were divided into two groups according to follow-up results: group A, with tumor recurrence within 1 year after resection; group B, without tumor recurrence within 1 year. Immunohistochemical stainings were performed using 11 kinds of monoclonal antibodies (AFP, c-erbB2, c-met, c-myc, HBsAg, HCV, Ki-67, MMP-2, nm23-H1, P53, and VEGF), and expressing intensities were quantitatively analyzed. Regression equation using factors affecting prognosis of HCC was constructed with binary logistic method. HCC patients undergoing percutaneous microwave coagulation therapy (PMCT) were also retrospectively analyzed (PMCT group). Immunohistochemical stainings of tumor biopsy samples were performed with molecules related to HCC prognosis, staining intensities were quantitatively analyzed, coincidence rate of prediction was calculated.
RESULTS: In resection group, the expressing intensities of c-myc, Ki-67, MMP-2 and VEGF in cancer tissue in group A were significantly higher than those in group B (t = 2.97, P = 0.01; t = 2.42, P = 0.03<0.05; t = 2.57, P = 0.02<0.05; t = 3.43, P = 0.004<0.01, respectively); the expressing intensities of 11 kinds of detected molecules in para-cancer tissue in groups A and B were not significantly different (P>0.05). The regression equation predicting prognosis of HCC is as follows: P(1) = 1/[1+e(-(3.663-0.412mycc-2.187Ki-67c-0.397vegfc))]. It demonstrates that prognosis of HCC in resection group was related with c-myc, Ki-67 and VEGF expressing intensity in cancer tissue. In PMCT group, the expressing intensities of c-myc, Ki-67 and VEGF in cancer tissue in group A were significantly higher than those in group B (t = 4.57, P = 0.000<0.01; t = 2.08, P = 0.04<0.05; t = 2.38, P = 0.02<0.05, respectively); the expressing intensities of c-myc, Ki-67 and VEGF in para-cancer tissue in groups A and B were not significantly different (P>0.05). The coincidence rate of patients undergoing PMCT in group A was 88.00% (22/25), in group B 68.75% (11/16), the total coincidence rate was 80.49% (33/41).
CONCLUSION: The regression equation is accurate and feasible and could be used for predicting prognosis of HCC, it helps to select treatment method (resection or PMCT) for HCC patients to realize individualized treatment to improve prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 15918184      PMCID: PMC4305834          DOI: 10.3748/wjg.v11.i20.3027

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme.

Authors:  J Cheng; J Luo; X Zhang; J Hu; H Hui; C Wang; A Stern
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

2.  Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center.

Authors:  Shinichi Ueno; Gen Tanabe; Kenshuke Nuruki; Makoto Oketani; Yasuji Komorizono; Hirohumi Hokotate; Yoshihiko Fukukura; Yoshirou Baba; Yasuhiro Imamura; Takashi Aikou
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

3.  Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus.

Authors:  J Zhou; Z Y Tang; J Fan; Z Q Wu; X M Li; Y K Liu; F Liu; H C Sun; S L Ye
Journal:  J Cancer Res Clin Oncol       Date:  2000-01       Impact factor: 4.553

4.  Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography.

Authors:  B K Kwak; H J Shim; E S Park; S A Kim; D Choi; H K Lim; C K Park; J W Chung; J H Park
Journal:  Invest Radiol       Date:  2001-08       Impact factor: 6.016

5.  Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma.

Authors:  Johan Ph Kuyvenhoven; Bart van Hoek; Eric Blom; Wim van Duijn; Roeland Hanemaaijer; Jan H Verheijen; Cornelis B H W Lamers; Hein W Verspaget
Journal:  Thromb Haemost       Date:  2003-04       Impact factor: 5.249

6.  Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway.

Authors:  Dipok Kumar Dhar; Hiroyuki Naora; Akira Yamanoi; Takashi Ono; Hitoshi Kohno; Hiroki Otani; Naofumi Nagasue
Journal:  Anticancer Res       Date:  2002 Jan-Feb       Impact factor: 2.480

7.  Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.

Authors:  George G Chen; Juanita L Merchant; Paul B S Lai; Rocky L K Ho; Xu Hu; Morihiro Okada; Sheng F Huang; Albert K K Chui; David J Law; Yong G Li; Wan Y Lau; Arthur K C Li
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

8.  A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma.

Authors:  Y Ishii; Y Nakasato; S Kobayashi; Y Yamazaki; T Aoki
Journal:  J Exp Clin Cancer Res       Date:  2003-09

9.  Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Lawrence E Harrison; Baburao Koneru; Phil Baramipour; Adrian Fisher; Alison Barone; Dorian Wilson; Andrew Dela Torre; Kyunghee C Cho; Daniel Contractor; Maria Korogodsky
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

10.  Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation.

Authors:  Chee Kiat Tan; Ngai Moh Law; Han Seong Ng; David Machin
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

View more
  8 in total

Review 1.  Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yihuan Luo; Fanghui Ren; Yongru Liu; Zhenhong Shi; Zhong Tan; Huojie Xiong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Application of restriction display PCR technique in the preparation of cDNA microarray probes.

Authors:  Zhao-Hui Sun; Wen-Li Ma; Bao Zhang; Yi-Fei Peng; Wen-Ling Zheng
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model.

Authors:  Volker Schmitz; Esther Raskopf; Maria Angeles Gonzalez-Carmona; Annabelle Vogt; Christian Rabe; Ludger Leifeld; Miroslaw Kornek; Tilman Sauerbruch; Wolfgang H Caselmann
Journal:  Gut       Date:  2006-06-29       Impact factor: 23.059

4.  The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus.

Authors:  Zhengbin Zhang; Dylan Harris; Virendra N Pandey
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.

Authors:  Choon-Yee Tan; Christina L Chang
Journal:  Lab Invest       Date:  2017-10-09       Impact factor: 5.662

Review 6.  Nm23/NDP kinases in hepatocellular carcinoma.

Authors:  Mathieu Boissan; Marie-Lise Lacombe
Journal:  J Bioenerg Biomembr       Date:  2006-08       Impact factor: 3.853

7.  EPMA position paper in cancer: current overview and future perspectives.

Authors:  Godfrey Grech; Xianquan Zhan; Byong Chul Yoo; Rostyslav Bubnov; Suzanne Hagan; Romano Danesi; Giorgio Vittadini; Dominic M Desiderio
Journal:  EPMA J       Date:  2015-04-15       Impact factor: 6.543

8.  Inhibition of HCV by the serpin antithrombin III.

Authors:  Mohammed Asmal; Michael Seaman; Wenyu Lin; Raymond T Chung; Norman L Letvin; Ralf Geiben-Lynn
Journal:  Virol J       Date:  2012-10-02       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.